Takeda Pharmaceutical Company Limited Stock BOERSE MUENCHEN
Equities
TKD
JP3463000004
Pharmaceuticals
Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
24.3 EUR | -0.33% | +0.12% | -5.83% |
May. 16 | Takeda Canada Completes LOI Stage for Post-Transplant Cytomegalovirus Treatment | MT |
May. 15 | Takeda Pharmaceutical's Dengue Vaccine Granted WHO Prequalification | MT |
Sales 2024 | 4,264B 27.18B 25.03B | Sales 2025 * | 4,161B 26.52B 24.43B | Capitalization | 6,481B 41.31B 38.05B |
---|---|---|---|---|---|
Net income 2024 | 144B 918M 846M | Net income 2025 * | 127B 811M 747M | EV / Sales 2024 | 1.54 x |
Net Debt 2024 * | 3,771B 24.03B 22.14B | Net Debt 2025 * | 4,125B 26.29B 24.22B | EV / Sales 2025 * | 2.55 x |
P/E ratio 2024 |
45.4
x | P/E ratio 2025 * |
48.6
x | Employees | - |
Yield 2024 * |
4.55% | Yield 2025 * |
4.63% | Free-Float | 99.12% |
Latest transcript on Takeda Pharmaceutical Company Limited
1 week | +0.12% | ||
Current month | -0.93% | ||
1 month | -1.65% | ||
3 months | -9.60% | ||
6 months | -5.47% | ||
Current year | -5.83% |
Managers | Title | Age | Since |
---|---|---|---|
Christophe Weber
CEO | Chief Executive Officer | 57 | 14-03-31 |
Gabriele Ricci
CTO | Chief Tech/Sci/R&D Officer | 45 | 22-01-31 |
Mwana Lugogo
CMP | Compliance Officer | 54 | 11-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 71 | 16-05-31 | |
Ian Clark
BRD | Director/Board Member | 62 | 18-12-31 |
Steven Gillis
BRD | Director/Board Member | 71 | 18-12-31 |
Date | Price | Change |
---|---|---|
24-05-27 | 24.3 | -0.33% |
24-05-24 | 24.38 | +0.16% |
24-05-23 | 24.34 | +0.62% |
24-05-22 | 24.19 | -0.58% |
24-05-21 | 24.33 | -0.69% |
Real-time BOERSE MUENCHEN, May 27, 2024 at 11:43 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+38.51% | 727B | |
+31.74% | 599B | |
-6.23% | 354B | |
+18.78% | 328B | |
+1.35% | 277B | |
+16.00% | 243B | |
+8.44% | 205B | |
-5.97% | 203B | |
+6.19% | 164B |
- Stock Market
- Equities
- 4502 Stock
- TKD Stock